Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.48 |
| ▸ | CETP | P11597 | 9/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | BCR | P11274 | 2/20 | 0.43 |
| ▸ | PRKCA | P17252 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6247148 | 0.90 | CETP (0.52) | PIM1PIM2CETPLMNAPOLB | |
| SCHEMBL13019852 | 0.90 | LMNA (0.44) | PIM1PIM2CETPABL1BCR | |
| SCHEMBL5670119 | 0.88 | CETP (0.54) | CETP | |
| SCHEMBL9169333 | 0.88 | PIM1 (0.42) | PIM1PIM2CETPABL1BCR | |
| SCHEMBL13144294 | 0.87 | CETP (0.52) | PIM1PIM2CETPABL1BCR | |
| SCHEMBL1617892 | 0.86 | TRPV1 (0.43) | PIM1PIM2CETPABL1BCR | |
| SCHEMBL5672060 | 0.86 | PIM1 (0.43) | PIM1PIM2CETPABL1BCR | |
| SCHEMBL1560 | 0.86 | CYP3A4 (0.48) | PIM1PIM2CETPABL1BCR | |
| SCHEMBL1608200 | 0.86 | PIM1 (0.46) | PIM1PIM2CETPABL1BCR | |
| SCHEMBL3278206 | 0.86 | CETP (0.52) | PIM1PIM2CETPABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260106221-A1 | LITHIUM SECONDARY BATTERY WITH ENHANCED SAFETY | SOLVAY SPECIALTY POLYMERS IT (IT) | 2026-04-16 | — | — | US | claimed |
| EP-4602667-A1 | LITHIUM SECONDARY BATTERY WITH ENHANCED SAFETY | Solvay Specialty Polymers Italy S.p.A. (IT) | 2025-08-20 | — | — | EP | claimed |
| WO-2024078976-A1 | LITHIUM SECONDARY BATTERY WITH ENHANCED SAFETY | SOLVAY SPECIALTY POLYMERS ITALY S.P.A. (IT) | 2024-04-18 | — | — | WO | claimed |
| EP-3900102-B1 | METHOD FOR EXCHANGING HEAT WITH A BATTERY USING FLUORINATED COMPOUNDS HAVING A LOW GWP | SOLVAY SPECIALTY POLYMERS IT (IT) | 2023-04-05 | — | — | EP | claimed |
| CN-115051032-A | Lithium ion battery electrolyte with negative electrode targeting passivation effect and preparation method thereof | 华中科技大学 | 2022-09-13 | — | — | CN | claimed |
| US-20220025240-A1 | METHOD OF MANUFACTURING SEMICONDUCTOR DEVICES USING A HEAT TRANSFER FLUID COMPRISING FLUORINATED COMPOUNDS HAVING A LOW GWP | Syensqo Specialty Polymers Italy S.p.A. (IT) | 2022-01-27 | — | — | US | claimed |
| US-20220021051-A1 | METHOD FOR EXCHANGING HEAT WITH A BATTERY USING FLUORINATED COMPOUNDS HAVING A LOW GWP | Syensqo Specialty Polymers Italy S.p.A. (IT) | 2022-01-20 | — | — | US | claimed |
| US-20210079534-A1 | METHOD, CELL, AND ELECTROLYTE FOR DINITROGEN CONVERSION | MONASH UNIVERSITY (AU) | 2021-03-18 | — | — | US | claimed |
| US-20260106221-A1 | LITHIUM SECONDARY BATTERY WITH ENHANCED SAFETY | SOLVAY SPECIALTY POLYMERS IT (IT) | 2026-04-16 | — | — | US | disclosed |
| EP-4602667-A1 | LITHIUM SECONDARY BATTERY WITH ENHANCED SAFETY | Solvay Specialty Polymers Italy S.p.A. (IT) | 2025-08-20 | — | — | EP | disclosed |
| US-20250112280-A1 | LITHIUM BATTERY ELECTROLYTE HAVING LITHIUM BORATE SALT AND TRIFLUOROACETAMIDE COMPOUND | Westlake University (CN) | 2025-04-03 | — | — | US | disclosed |
| EP-4471923-A1 | LITHIUM BATTERY ELECTROLYTE HAVING LITHIUM BORATE SALT AND TRIFLUOROACETAMIDE COMPOUND | Westlake University (CN) | 2024-12-04 | — | — | EP | disclosed |
| US-12036563-B2 | Process for separating mixtures of solids | SOLVAY SPECIALTY POLYMERS USA, LLC (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2024078976-A1 | LITHIUM SECONDARY BATTERY WITH ENHANCED SAFETY | SOLVAY SPECIALTY POLYMERS ITALY S.P.A. (IT) | 2024-04-18 | — | — | WO | disclosed |
| EP-0428708-B1 | PROCESS FOR PREPARING A POLYMER HAVING PERFLUOROCYCLOBUTANE RINGS AND POLYMERS CONTAINING PERFLUOROCYCLOBUTANE RINGS | DOW CHEMICAL CO (US) | 1994-10-05 | — | — | EP | disclosed |
| EP-0428706-B1 | PERFLUOROVINYL COMPOUNDS | DOW CHEMICAL CO (US) | 1994-07-13 | — | — | EP | disclosed |
| US-5162468-A | Polymers containing perfluorocyclobutane rings | THE DOW CHEMICAL COMPANY (US) | 1992-11-10 | — | — | US | disclosed |
| US-5159038-A | Flexibility, tensile strength | DOW CHEMICAL COMPANY (US) | 1992-10-27 | — | — | US | disclosed |
| US-5037917-A | Polymerizing Monomers Containing At Least Two Perfluorovinyl Groups, Then Heating To Form Perfluorocyclobutane Rings | THE DOW CHEMICAL COMPANY (US) | 1991-08-06 | — | — | US | disclosed |
| US-5023380-A | Monomer for thermoplastic resin | THE DOW CHEMICAL COMPANY (US) | 1991-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250112280-A1 | LITHIUM BATTERY ELECTROLYTE HAVING LITHIUM BORATE SALT AND TRIFLUOROACETAMIDE COMPOUND | HCN2, SLC9A5, SLC9B2 | PIM1 3703/4885PIM2 3629/4885CETP 2773/4885 |
| US-20260106221-A1 | LITHIUM SECONDARY BATTERY WITH ENHANCED SAFETY | BCL6B, CLCN2, SLC9A2 | PIM1 2816/4885PIM2 2058/4885CETP 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.